ReviewCurrent hypertension reports2003
Impact of the obesity epidemic on hypertension and renal disease.
Review in Current hypertension reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03912909 (Effects of SGLT-2 Inhibition on Sympathetic Nervous System Activity in Humans), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of SGLT-2 Inhibition on Sympathetic Nervous System Activity in Humans
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2008Pooled it
- Electrolyte Imbalances and Metabolic Emergencies in Obesity: Mechanisms and Clinical Implications.Diseases (Basel, Switzerland) · 2025Review
- The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes.Pharmaceutics · 2023Review
- Soluble (Pro)Renin Receptor in Hypertension.Nephron · 2023Review
- Development and Validation of a Nomogram-Based Prognostic Model to Predict High Blood Pressure in Children and Adolescents-Findings From 342,736 Individuals in China.Frontiers in cardiovascular medicine · 2022Article
- The Pivotal Role of Adipocyte-Na K peptide in Reversing Systemic Inflammation in Obesity and COVID-19 in the Development of Heart Failure.Antioxidants (Basel, Switzerland) · 2020Review
- Synergistical action of the β2 adrenoceptor and fatty acid binding protein 2 polymorphisms on the loss of glomerular filtration rate in Chinese patients with type 2 diabetic nephropathy.International urology and nephrology · 2018Article
- Evaluation of lipid profiles and hematological parameters in hypertensive patients: Laboratory-based cross-sectional study.SAGE open medicine · 2018Article
- Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis.Journal of diabetes and metabolic disorders · 2017Review
- Angiotensin AT2 receptor agonist prevents salt-sensitive hypertension in obese Zucker rats.American journal of physiology. Renal physiology · 2015Article
- The Intricate Network of Adipokines and Stroke.International journal of endocrinology · 2015Review
- The pathophysiology of hypertension in patients with obesity.Nature reviews. Endocrinology · 2014Review
- Obesity, hypertension, and chronic kidney disease.International journal of nephrology and renovascular disease · 2014Review
- Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats.Kidney international · 2013Article
- Relationship between anthropometric measures and cardiovascular risk factors in children and adolescents.Arquivos brasileiros de cardiologia · 2013Article
- Renal denervation abolishes the age-dependent increase in blood pressure in female intrauterine growth-restricted rats at 12 months of age.Hypertension (Dallas, Tex. : 1979) · 2013Article
- Obesity and diabetic kidney disease.The Medical clinics of North America · 2013Review
- AT2 receptor non-peptide agonist C21 promotes natriuresis in obese Zucker rats.Hypertension research : official journal of the Japanese Society of Hypertension · 2012Article
- Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women.The Journal of clinical endocrinology and metabolism · 2012Article
- Central obesity and albuminuria: both cross-sectional and longitudinal studies in Chinese.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Excess weight gain is a major cause of increased blood pressure in most patients with essential hypertension, and also greatly increases the risk for renal disease. Obesity raises blood pressure by increasing renal tubular reabsorption, impairing pressure natriuresis, causing volume expansion due to activation of the sympathetic nervous system and renin-angiotensin system, and by physical compression of the kidneys, especially when visceral obesity is present. The mechanisms of sympathetic nervous system activation in obesity may be due, in part, to hyperleptinemia that stimulates the hypothalamic pro-opiomelanocortin pathway. With prolonged obesity, there may be a gradual loss of nephron function that worsens with time and exacerbates hypertension. Weight reduction is an essential first step in the management of obesity hypertension and renal disease. Special considerations for the obese patient, in addition to adequately controlling the blood pressure, include correction of the metabolic abnormalities and protection of the kidneys from further injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.